# Medication Guide for Palliative Care

## Essential Medications by Category

### Opioid Analgesics

#### Strong Opioids
**Morphine** (reference standard)
- **PO**: 5-10mg q4h regular + 2.5-5mg q1h PRN breakthrough
- **SC/IV**: 2.5-5mg q4h regular + 1-2.5mg q1h PRN breakthrough
- **Conversion**: PO:SC = 2:1, PO:IV = 3:1

**Oxycodone**
- **PO**: 2.5-5mg q4h (1.5x more potent than morphine)
- **Conversion**: Morphine to oxycodone = 1.5:1

**Hydromorphone**
- **PO**: 1-2mg q4h (5x more potent than morphine)
- **SC/IV**: 0.25-0.5mg q4h
- **Useful**: Renal impairment, morphine intolerance

**Fentanyl**
- **Patch**: 12-25mcg/h q72h (for stable pain, morphine equivalent â‰¥60mg/day)
- **Conversion**: 100:1 ratio (100mg oral morphine = 25mcg/h patch)
- **Onset**: 12-24h for patch effect

#### Weak Opioids
**Tramadol**
- **Dose**: 50-100mg q6-8h (max 400mg/day)
- **Caution**: Serotonin syndrome risk, seizure threshold lowering

**Codeine**
- **Dose**: 15-60mg q4-6h
- **Limitation**: CYP2D6 polymorphism affects conversion to morphine

### Anti-emetics

**Ondansetron** (5-HT3 antagonist)
- **Indication**: Chemotherapy, radiation-induced nausea
- **Dose**: 4-8mg q8h PO/IV/SL
- **Caution**: QT prolongation

**Metoclopramide** (D2 antagonist)
- **Indication**: Delayed gastric emptying, functional bowel obstruction
- **Dose**: 10mg q6h PO/SC/IV
- **Caution**: Extrapyramidal side effects, tardive dyskinesia

**Haloperidol** (D2 antagonist)
- **Indication**: Chemical causes (hypercalcemia, uremia)
- **Dose**: 0.5-1mg q8h PO/SC/IV
- **Advantage**: Minimal sedation

**Olanzapine** (atypical antipsychotic)
- **Indication**: Refractory nausea/vomiting
- **Dose**: 2.5-5mg daily PO
- **Advantage**: Multiple neurotransmitter targets

### Anxiolytics

**Lorazepam**
- **Indication**: Anxiety, anticipatory nausea, dyspnea, agitation
- **Dose**: 0.5-2mg q4-6h PO/SL/IV PRN
- **Advantage**: No active metabolites, short half-life

**Midazolam**
- **Indication**: Terminal restlessness, subcutaneous infusion
- **Dose**: 2.5-5mg SC q2-4h PRN or 10-60mg/24h CSCI
- **Route**: Preferred for subcutaneous use

### Laxatives

**Docusate** (stool softener)
- **Dose**: 100mg BID PO
- **Indication**: Prevention of constipation
- **Mechanism**: Surfactant action

**Senna** (stimulant)
- **Dose**: 2 tablets (17.2mg) HS, increase to BID
- **Indication**: Active constipation
- **Caution**: Cramping, electrolyte loss

**Lactulose** (osmotic)
- **Dose**: 15-30ml BID PO
- **Indication**: Hepatic encephalopathy, chronic constipation
- **Side effect**: Bloating, flatulence

**Polyethylene Glycol (PEG)**
- **Dose**: 17g daily in 240ml liquid
- **Advantage**: Minimal electrolyte disturbance

### Corticosteroids

**Dexamethasone**
- **Indications**: Cerebral edema, spinal cord compression, appetite stimulation
- **Dose**: 4-16mg daily PO/IV (higher for emergencies)
- **Duration**: Short-term use preferred

**Prednisolone**
- **Indications**: Anti-inflammatory, appetite stimulation
- **Dose**: 5-40mg daily PO
- **Equivalent**: 5mg prednisolone = 0.75mg dexamethasone

### Adjuvant Analgesics

**Gabapentin**
- **Indication**: Neuropathic pain
- **Dose**: Start 100mg TID, titrate to 300-800mg TID
- **Titration**: Increase every 3-5 days

**Pregabalin**
- **Indication**: Neuropathic pain
- **Dose**: Start 75mg BID, titrate to 150-300mg BID
- **Advantage**: Faster titration than gabapentin

**Amitriptyline**
- **Indication**: Neuropathic pain, depression, insomnia
- **Dose**: 10-25mg HS, titrate to 75-150mg
- **Caution**: Anticholinergic effects, cardiac conduction

## Dosing Guidelines

### Opioid Dose Calculations

#### Morphine Equivalent Daily Dose (MEDD)
- **Purpose**: Standardize opioid prescribing
- **Calculation**: Sum all opioids as morphine equivalents
- **High-risk**: >90mg MEDD requires careful monitoring

#### Breakthrough Pain Dosing
- **Principle**: 10-15% of total daily opioid dose
- **Frequency**: q1h PRN for immediate-release
- **Adjustment**: If >3 breakthrough doses/day, increase regular dose

#### Opioid Rotation
**Indications**: Inadequate analgesia, intolerable side effects, route change
**Method**: 
1. Calculate current MEDD
2. Apply conversion ratio
3. Reduce new opioid by 25-50% (incomplete cross-tolerance)
4. Provide appropriate breakthrough dosing

### Route Considerations

#### Oral Administration
- **Preferred**: Convenient, cost-effective
- **Limitations**: Swallowing difficulties, nausea, absorption issues

#### Sublingual
- **Indications**: Dysphagia, nausea, rapid onset needed
- **Drugs**: Lorazepam, ondansetron, select opioids

#### Subcutaneous
- **Indications**: Cannot take oral, avoid IV access
- **Advantages**: Home-friendly, continuous infusion possible
- **Volume**: <2ml per injection site

#### Continuous Subcutaneous Infusion (CSCI)
- **Indications**: Multiple medications, consistent delivery
- **Compatible combinations**: Verify compatibility charts
- **Site care**: Rotate every 2-3 days

## Side Effects Management

### Opioid-Related

**Constipation**
- **Prevention**: Prophylactic laxatives for all patients
- **Treatment**: Increase laxatives, consider methylnaltrexone

**Nausea**
- **Timing**: Usually resolves in 3-5 days
- **Treatment**: Anti-emetics, dose adjustment

**Sedation**
- **Timing**: Usually improves with tolerance
- **Management**: Dose adjustment, stimulants if persistent

**Respiratory Depression**
- **Risk factors**: Opioid-naive, rapid titration, renal impairment
- **Monitoring**: Respiratory rate, oxygen saturation
- **Reversal**: Naloxone 0.04-0.4mg IV (dilute and titrate)

### Drug-Specific Monitoring

**Haloperidol**: Extrapyramidal symptoms, QT prolongation
**Metoclopramide**: Tardive dyskinesia (limit to 5 days if possible)
**Corticosteroids**: Hyperglycemia, mood changes, immunosuppression
**Gabapentin/Pregabalin**: Sedation, peripheral edema, weight gain

## Drug Interactions

### Important Interactions

**CYP450 Considerations**
- **CYP3A4 inhibitors**: Increase fentanyl, oxycodone levels
- **CYP2D6 polymorphism**: Affects codeine, tramadol metabolism

**Serotonin Syndrome Risk**
- **Combinations**: Tramadol + SSRIs, MAOIs
- **Symptoms**: Hyperthermia, rigidity, altered mental status

**CNS Depression**
- **Additive effects**: Opioids + benzodiazepines + alcohol
- **Monitoring**: Increased sedation, respiratory depression

### Renal/Hepatic Impairment

**Renal Impairment**
- **Avoid**: Morphine (accumulation of metabolites)
- **Prefer**: Fentanyl, hydromorphone
- **Adjust**: All renally cleared medications

**Hepatic Impairment**
- **Caution**: All opioids, reduce initial doses
- **Monitor**: Enhanced/prolonged effects

## Emergency Medications

### Opioid Overdose
**Naloxone (Narcan)**
- **Dose**: 0.04-0.4mg IV every 2-3 minutes
- **Duration**: 30-90 minutes (shorter than most opioids)
- **Caution**: May precipitate withdrawal, repeat dosing often needed

### Severe Agitation/Delirium
**Haloperidol + Lorazepam**
- **Combination**: Haloperidol 2-5mg + Lorazepam 1-2mg IM/IV
- **Monitoring**: Respiratory status, vital signs

### Hypercalcemia
**IV Hydration + Bisphosphonates**
- **Acute**: NS 1-2L + Furosemide 20-40mg IV
- **Bisphosphonate**: Zoledronic acid 4mg IV over 15 minutes

## Storage and Safety

### Controlled Substances
- **Storage**: Locked cabinet or safe
- **Disposal**: Return to pharmacy or DEA take-back events
- **Documentation**: Accurate counting and record-keeping

### Patient/Family Education
- **Safe use**: Exact dosing, timing, route
- **Storage**: Away from children, temperature considerations
- **Disposal**: Unused medications, expired drugs
- **Emergency contacts**: When to call, overdose recognition

[Return to Table of Contents](../toc.md)
